Insights Into the Molecular Mechanism of Triptan Transport by P-glycoprotein

Overview

Journal J Pharm Sci

Publisher Elsevier

Specialties Pharmacology
Pharmacy

Date 2017 Mar 12

PMID 28283434

Citations 11

Authors

Laura A Wilt

Diana Nguyen

Arthur G Roberts

Affiliations

Soon will be listed here.

Abstract

The P-glycoprotein (Pgp) transporter reduces the penetration of a chemically diverse range of neurotherapeutics at the blood-brain barrier, but the molecular features of drugs and drug-Pgp interactions that drive transport remain to be clarified. In particular, the triptan neurotherapeutics, eletriptan (ETT) and sumatriptan (STT), were identified to have a >10-fold difference in transport rates despite being from the same drug class. Consistent with these transport differences, ETT activated Pgp-mediated ATP hydrolysis ∼2-fold, whereas STT slightly inhibited Pgp-mediated ATP hydrolysis by ∼10%. The interactions between them were also noncompetitive, suggesting that they occupy different binding sites on the transporter. Despite these differences, protein fluorescence spectroscopy revealed that the drugs have similar affinity to the transporter. NMR with Pgp and the drugs showed that they have distinct interactions with the transporter. Tertiary conformational changes probed by acrylamide quenching of Pgp tryptophan fluorescence with the drugs and a nonhydrolyzable ATP analog implied that the STT-bound Pgp must undergo larger conformational changes to hydrolyze ATP than ETT-bound Pgp. These results and previous transport studies were used to build a conformationally driven model for triptan transport with Pgp where STT presents a higher conformational barrier for ATP hydrolysis and transport than ETT.

Citing Articles

Regional distribution of unbound eletriptan and sumatriptan in the CNS and PNS in rats: implications for a potential central action.

Svane N, Ballgren F, Ginosyan A, Kristensen M, Brodin B, Loryan I J Headache Pain. 2024; 25(1):187.

PMID: 39478486 PMC: 11523665. DOI: 10.1186/s10194-024-01894-0.

The putative proton-coupled organic cation antiporter is involved in uptake of triptans into human brain capillary endothelial cells.

Svane N, Pedersen A, Rodenberg A, Ozgur B, Saaby L, Bundgaard C Fluids Barriers CNS. 2024; 21(1):39.

PMID: 38711118 PMC: 11071266. DOI: 10.1186/s12987-024-00544-6.

Utilizing surface plasmon resonance as a novel method for monitoring P-glycoprotein efflux.

Nguyen P, Cui S, Kozarich A, Rautio A, Roberts A, Xiong M Front Biophys. 2024; 2.

PMID: 38645731 PMC: 11027885. DOI: 10.3389/frbis.2024.1367511.

Drug-Induced Conformational Dynamics of P-Glycoprotein Underlies the Transport of Camptothecin Analogs.

Mensah G, Schaefer K, Bartlett M, Roberts A, King G Int J Mol Sci. 2023; 24(22).

PMID: 38003248 PMC: 10671697. DOI: 10.3390/ijms242216058.

The Impact of P-Glycoprotein on Opioid Analgesics: What's the Real Meaning in Pain Management and Palliative Care?.

Coluzzi F, Scerpa M, Rocco M, Fornasari D Int J Mol Sci. 2022; 23(22).

PMID: 36430602 PMC: 9695906. DOI: 10.3390/ijms232214125.

References

Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R . Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999; 368(2-3):259-68. DOI: 10.1016/s0014-2999(99)00026-6. View

Romsicki Y, Sharom F . The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry. 1999; 38(21):6887-96. DOI: 10.1021/bi990064q. View

Sonveaux N, Vigano C, Shapiro A, Ling V, Ruysschaert J . Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein. A tryptophan fluorescence quenching analysis. J Biol Chem. 1999; 274(25):17649-54. DOI: 10.1074/jbc.274.25.17649. View

Barnes N, Sharp T . A review of central 5-HT receptors and their function. Neuropharmacology. 1999; 38(8):1083-152. DOI: 10.1016/s0028-3908(99)00010-6. View

Hrycyna C, Ramachandra M, Germann U, Cheng P, Pastan I, Gottesman M . Both ATP sites of human P-glycoprotein are essential but not symmetric. Biochemistry. 1999; 38(42):13887-99. DOI: 10.1021/bi991115m. View

Gimi K, Urbatsch I, Gros P, Senior A . Large scale purification of detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of nucleotide binding properties of wild-type, Walker A, and Walker B mutant proteins. J Biol Chem. 1999; 274(49):34711-8. DOI: 10.1074/jbc.274.49.34711. View

Martin C, Berridge G, Higgins C, Mistry P, Charlton P, Callaghan R . Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol. 2000; 58(3):624-32. DOI: 10.1124/mol.58.3.624. View

Liu R, Siemiarczuk A, Sharom F . Intrinsic fluorescence of the P-glycoprotein multidrug transporter: sensitivity of tryptophan residues to binding of drugs and nucleotides. Biochemistry. 2000; 39(48):14927-38. DOI: 10.1021/bi0018786. View

Seelig A, Landwojtowicz E . Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci. 2000; 12(1):31-40. DOI: 10.1016/s0928-0987(00)00177-9. View

10.

Mayer M, Meyer B . Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc. 2001; 123(25):6108-17. DOI: 10.1021/ja0100120. View

11.

Bendayan R, Lee G, Bendayan M . Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech. 2002; 57(5):365-80. DOI: 10.1002/jemt.10090. View

12.

Tepper S, Rapoport A, Sheftell F . Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002; 59(7):1084-8. DOI: 10.1001/archneur.59.7.1084. View

13.

Loo T, Bartlett M, Clarke D . Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains. J Biol Chem. 2002; 278(3):1575-8. DOI: 10.1074/jbc.M211307200. View

14.

Mahar Doan K, Humphreys J, Webster L, Wring S, Shampine L, Serabjit-Singh C . Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002; 303(3):1029-37. DOI: 10.1124/jpet.102.039255. View

15.

Loo T, Bartlett M, Clarke D . Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J Biol Chem. 2003; 278(16):13603-6. DOI: 10.1074/jbc.C300073200. View

16.

Evans D, OConnor D, Lake B, Evers R, Allen C, Hargreaves R . Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003; 31(7):861-9. DOI: 10.1124/dmd.31.7.861. View

17.

Sharom F, Russell P, Qu Q, Lu P . Fluorescence techniques for studying membrane transport proteins: the P-glycoprotein multidrug transporter. Methods Mol Biol. 2003; 227:109-28. DOI: 10.1385/1-59259-387-9:109. View

18.

Safa A . Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents. 2004; 4(1):1-17. PMC: 4447203. DOI: 10.2174/1568011043482142. View

19.

Lee G, Bendayan R . Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res. 2004; 21(8):1313-30. DOI: 10.1023/b:pham.0000036905.82914.8e. View

20.

Claasen B, Axmann M, Meinecke R, Meyer B . Direct observation of ligand binding to membrane proteins in living cells by a saturation transfer double difference (STDD) NMR spectroscopy method shows a significantly higher affinity of integrin alpha(IIb)beta3 in native platelets than in.... J Am Chem Soc. 2005; 127(3):916-9. DOI: 10.1021/ja044434w. View